GS vs PRLD · P/E 20, $324.25B cap vs rev $6.5M
Goldman Sachs Group Inc (GS) versus Prelude Therapeutics Inc (PRLD) — a side-by-side from cached financials, not a winner call.
Goldman Sachs Group Inc (GS) is a capital markets company listed on NYSE. It is led by David Solomon.
Prelude Therapeutics Inc (PRLD) is a biotechnology company listed on NASDAQ.
GS does not have a complete income-statement cache yet.
Latest reported PRLD revenue for 2025-09-30 was $6.5M. Net income was -$83.0M. Revenue was up 116.7% from 2024-09-30 to 2025-09-30. PRLD currently screens at market cap $346.5M.
GS currently screens at market cap $324.25B and trailing P/E 20.1. PRLD currently screens at market cap $346.5M.
Not investment advice. Open the GS and PRLD stock pages for the full models.
Not investment advice.